A5010158325- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Viral Infectious Diseases and Gene Expression in Insects
- Hematopoietic Stem Cell Transplantation
- Advancements in Semiconductor Devices and Circuit Design
- Silicon Carbide Semiconductor Technologies
- Virus-based gene therapy research
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Integrated Circuits and Semiconductor Failure Analysis
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Biomedical Ethics and Regulation
- Nanowire Synthesis and Applications
- Viral-associated cancers and disorders
- Mesenchymal stem cell research
- SARS-CoV-2 and COVID-19 Research
- Cancer Immunotherapy and Biomarkers
- COVID-19 and healthcare impacts
- Cytomegalovirus and herpesvirus research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Fred Hutch Cancer Center
2016-2025
University of Washington
2019-2025
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
2021-2024
University of Washington Medical Center
2020-2023
Seattle University
2019-2022
Seattle Cancer Care Alliance
2020-2021
Clinical Research Management
2021
Cancer Research Center
2021
Centre Hospitalier Universitaire de Lille
2011-2019
Université de Lille
2015-2018
The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based immunophenotype and cytogenetic/molecular markers; risk assessment stratification risk-adapted therapy; treatment strategies Philadelphia chromosome (Ph)-positive Ph-negative both adolescent young adult patients; supportive care considerations. Given complexity regimens required measures, Panel recommends that patients be treated at a specialized cancer center with expertise in...
Abstract CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy in patients with relapsed/refractory B-cell malignancies; however, it is associated toxicities including cytokine release syndrome (CRS), neurotoxicity, and impaired hematopoietic recovery. The latter high-grade cytopenias requiring extended growth factor or transfusional support, potentially leading to additional complications such as infection hemorrhage. To date, the factors...
Given the global surge in autoimmune diseases, it is critical to evaluate emerging therapeutic interventions. Despite numerous new targeted immunomodulatory therapies, comprehensive approaches apply and effects of these treatments longitudinally are lacking. Here, we leveraged advances programmable-phage immunoprecipitation methodology explore modulation, or lack thereof, autoantibody profiles, proteome-wide, both health disease. Using a custom set over 730,000 human-derived peptides,...
Key Points The toxicity of allo-HCT in patients with prior CAR-T therapy was not higher than what is expected these high-risk patients. In ALL patients, there seems to be a benefit from earlier utilization after therapy.
Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). However, limited durability response and prevalent toxicities remain problematic. Identifying who are at high risk disease progression, toxicity, death would inform treatment decisions. Although the cumulative illness rating scale (CIRS) been shown to correlate in malignancies, no prognostic score independently validated CART recipients. We...
Abstract Background Hematopoietic cell transplant (HCT) or chimeric antigen receptor (CAR) T-cell therapy recipients have high morbidity from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. There are limited data on outcomes SARS-CoV-2 infection shortly before cellular and uncertainty whether to delay therapy. Methods We conducted a retrospective cohort study of patients with within 90 days HCT CAR-T-cell between January 2020 November 2022. characterized the kinetics...
CD19-directed chimeric antigen receptor-engineered (CD19 CAR) T-cell therapy elicits high response rates but fails to induce durable responses in most adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). In a previous clinical trial (NCT01865617), we observed anti-CAR immune associated impaired vivo CAR expansion after second infusions. Because these CD8+ were predominantly directed at peptides derived from the murine single chain variable fragment (scFv)...
Abstract Background The epidemiology of cytomegalovirus (CMV) after chimeric antigen receptor–modified T-cell immunotherapy (CARTx) is poorly understood owing to a lack routine surveillance. Methods We prospectively enrolled 72 adult CMV-seropositive CD19-, CD20-, or BCMA-targeted CARTx recipients and tested plasma samples for CMV before weekly up 12 weeks CARTx. assessed CMV-specific cell-mediated immunity (CMV-CMI) 2 4 CARTx, using an interferon γ release assay quantify responses IE-1...
More than half of the patients treated with CD19-targeted chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL) do not achieve durable remission, which may be partly due to PD-1/PD-L1-associated CAR dysfunction. We report data from a phase 1 clinical trial (NCT02706405), in adults LBCL were autologous CD19 T cells (JCAR014) combined escalating doses anti-PD-L1 monoclonal antibody, durvalumab, starting either before or after infusion. The addition durvalumab...